

Supplementary Table 1. Physician's Global Assessment of Clinical Condition (1)

Grade		Description	Response [#]
0	Completely clear	No evidence of disease; 100% improvement	CR
1	Almost clear	Very significant clearance ($\geq 90\%$ to $< 100\%$); only traces of disease remain	PR
2	Marked improvement	Significant improvement ($\geq 75\%$ to $< 90\%$); some evidence of disease remains	PR
3	Moderate Improvement	Intermediate between slight and marked improvement; ($\geq 50\%$ to $< 75\%$)	PR
4	Slight Improvement	Some improvement ($\geq 25\%$ to $< 50\%$); significant evidence of disease remains	SD
5	No change	Disease has not changed from baseline condition ($\pm < 25\%$)	SD
6	Worse	Disease is worse than at baseline evaluation by $\geq 25\%$ or more	PD

[#] Confirmation over at least 4 study weeks required except for a last assessment on study if progressive disease; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease

1. Prince HM, McCormack C, Ryan G, et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. *Australas J Dermatol* 2001;42(2):91-7.

Supplementary Table 2. Patient Characteristics

ID	CTCL type at Diagnosis	Stage ¹	Age	M/F	ECOG Performance Status	Diagnosis of CTCL to enrolment (months)	Absolute WCC (lymphocyte count) X 10 ⁹ /L	Prior Radiotherapy	Prior PUVA	Prior UVB	Prior Systemic Treatment
20100101	SS with large cell transformation	IVa	79	F	2	5	15 (2.1)	No	No	No	Methotrexate
20100102	MF	IIb	53	F	1	2.5	10 (1.7)	Yes	No	No	None
20100103	MF	Ib - Patch	68	F	0	102	5.3 (1.4)	No	Yes	Yes	None
20100104	MF	IIb	78	F	0	12	6.6 (1.1)	Yes	No	No	None
20100105	SS	IVa	56	F	1	5	12.8 (2.3)	No	No	No	Interferon alpha ₂
20100106	Granulomatous MF	IIb	35	F	0	20	4.3 (1.4)	No	No	No	cyclophosphamide, vincristine, doxorubicin, cytarabine, hyper CVAD, methotrexate, denileukin diftitox
20100107	SS	III	60	M	0	22	12.4. (2.6)	No	No	No	Extracorporeal photopheresis (ECP)
20100109	MF	IVa	57	F	1	108	6.4 (1.1)	Yes	No	No	CVP, denileukin diftitox, romidepsin (depsipeptide)
20100110	MF	Ib - Plaque	59	M	1	23	10.5 (1.6)	No	Yes	Yes	Prednisolone, azathioprine
502-103	MF	III	74	F	1	102	4.4 (1.5)	No	Yes	No	Prednisone, interferon alpha, gemcitabine

ID = individual patient identification number; CTCL = cutaneous T-cell lymphoma; M = male; F = female; ECOG = Eastern Cooperative Oncology Group; PUVA = Psoralen ultraviolet A therapy; UVB = ultraviolet light B; MF = mycosis fungoides; SS = Sezary syndrome; WCC = white cell count; hyper CVAD = fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; CVP = cyclophosphamide/vincristine/prednisolone

Supplementary Table 3. Differentially expressed genes that respond to panobinostat over time in all patients.

Affymetrix ID	Gene Symbol	Basic Function	Gene Expression values				p-value	Q-value
			T0 Baseline	T4 vs T0	T8 vs T0	T24 vs T0		
230061_at	TM4SF18	Cell surface receptor implicated in cell proliferation and activation, cellular motility and adhesion, tumour cell metastasis	7.75	-1.80	-2.99	-1.47	3.46E-07	0.0077
221942_s_at	GUCY1A3	Angiogenesis	9.61	-1.60	-1.48	-1.16	2.07E-06	0.0140
228665_at	CYYR1	No known function	8.86	-1.39	-1.74	-1.01	1.53E-06	0.0140
214920_at	KIAA0960	Hypothetical protein	5.69	-0.74	-1.62	-0.34	3.53E-06	0.0156
205609_at	ANGPT1	Angiogenesis	5.61	-1.21	-1.41	-0.60	9.33E-06	0.0344
243813_at	SEPTIN 10	membrane dynamics, apoptosis, cytoskeletal remodelling	5.88	-1.55	-2.16	-0.41	1.92E-05	0.0608
209540_at	IGF1	cellular signalling involved in regulating cell proliferation and apoptosis	7.19	-1.18	-1.83	-0.44	2.89E-05	0.0711
215073_s_at	NR2F2	Transcriptional regulation	5.58	-1.72	-1.59	-1.45	2.77E-05	0.0711
201468_s_at	NQO1	Protection against oxidative stress	7.68	-0.75	-0.75	0.54	3.76E-05	0.0791
210644_s_at	LAIR1	Ig-like receptor involved in immune interactions	5.53	-0.78	-1.25	-1.03	4.58E-05	0.0791
222561_at	LANCL2	Implicated in cellular drug sensitivity	4.36	-0.97	-1.08	-0.29	4.98E-05	0.0791
225619_at	FLJ30046	Hypothetical protein	3.63	0.93	1.07	-0.55	6.07E-05	0.0791
225840_at	TEF	anti-apoptotic transcription factor	6.05	-1.84	-1.97	-0.87	5.50E-05	0.0791
227088_at	PDE5A	cGMP-specific signalling	5.44	-1.38	-0.74	-1.60	5.76E-05	0.0791
227827_at	SORBS2	Promotes cell survival	5.42	-2.06	-0.45	-2.67	6.03E-05	0.0791
239650_at	NAP5	Regulation of actin assembly	4.12	-0.66	-1.13	-0.86	7.65E-05	0.0941
208712_at	CCND1	cell cycle	8.94	-0.77	-0.69	0.09	8.75E-05	0.1020
224463_s_at	C11orf70	Hypothetical protein	4.19	-0.32	0.35	-1.01	0.00011	0.1210
227780_s_at	ECMS2	Hypothetical protein	7.66	-1.24	-1.73	-1.12	0.00011	0.1210
212771_at	C10orf38	Hypothetical protein	6.85	-1.03	-0.53	-0.31	0.00012	0.1257
204900_x_at	SAP30	Transcriptional regulation	7.18	1.27	0.36	-0.43	0.00016	0.1442
222752_s_at	C1orf75	Hypothetical protein	6.08	1.21	0.67	-0.08	0.00017	0.1442
219543_at	MAWDBP	Putative MAPK activator	5.31	-0.62	-0.82	0.07	0.00018	0.1463

Shown is the Affymetrix ID with corresponding gene symbol and known basic function of the encoded protein.